Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Effient(TM) is Now Available in Pharmacies

Daiichi Sankyo
Posted on: 06 Aug 09Eli Lilly and Company
Posted on: 06 Aug 09

Effient(TM) Reduces Thrombotic Cardiovascular Events in Patients with Acute Coronary Syndromes Managed with Common Artery-Opening Procedure

PARSIPPANY, N.J. and INDIANAPOLIS, Aug 05, 2009 /PRNewswire-FirstCall via COMTEX News Network/ Effient(TM) (prasugrel), a new antiplatelet medicine, is now available in pharmacies across the United States, Daiichi Sankyo, Inc. and Eli Lilly and Company (NYSE: LLY) announced today.

The U.S. Food and Drug Administration approved Effient tablets on July 10 for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromes (ACS) who are managed with an artery-opening procedure known as percutaneous coronary intervention (PCI). PCI usually includes the placement of a stent to help keep the artery open.

"Before Effient was available, physicians and patients had limited antiplatelet therapy options. Effient is a new treatment option to help reduce an ACS patient's risk of having a heart attack or stent thrombosis after PCI," said Dr. Dean Kereiakes, medical director at The Christ Hospital Heart and Vascular Center in Cincinnati, OH. "Different patients respond differently to medications, so it's important to have multiple options for treating heart disease given how pervasive and costly this condition is in our society."

Effient helps keep blood platelets from clumping together and developing a blockage in an artery. Taking Effient along with aspirin after PCI has been shown to reduce the chances of having a cardiac event such as a heart attack or stent-related blood clots in patients with ACS. Bleeding is the most common side effect of Effient. Some bleeding can be life-threatening, and even fatal.

"We are excited about bringing Effient, to patients and their healthcare professionals," said Enrique Conterno, president of Lilly USA, LLC. "We will work closely with healthcare professionals to ensure they understand how Effient works and who the appropriate patients are to receive this innovative treatment."

"We recognize the need for practical patient support and education during this difficult time in patients' lives, following a major cardiovascular event and possibly having a stent placed in an artery," said Joe Pieroni, president and chief executive officer for Daiichi Sankyo, Inc. "We are dedicated to developing highly relevant, evidence-based programs to help patients recover as well as regain their health and confidence."

Important Safety Information about Effient

Antiplatelet medicines, including Effient, can increase the risk of bleeding. If patients have unexplained or excessive bleeding while on Effient, they should contact their doctor right away as some bleeding can be serious, and sometimes may lead to death. Patients should not take Effient if they have a stomach ulcer or other conditions that cause bleeding or if they have a history of stroke or "mini-stroke" (transient ischemic attack or TIA).

If patients are 75 or older, or if they weigh less than 132 pounds, or if they are taking anticoagulants (eg, warfarin) or taking NSAIDs (eg, ibuprofen or naproxen) for a long time, they should talk to their doctor, as they may be at an increased risk of bleeding.

If patients plan to have surgery or a dental procedure, they should tell their doctors that they are taking Effient.

Patients should not stop taking Effient without first talking to the doctor who prescribed it for them, as this may result in increased risk of a clot in their stent, a heart attack or death.

Patients should get medical attention right away if they develop any of the following unexpected symptoms: fever, weakness, yellowing of the skin or eyes, or if skin becomes very pale or dotted with purple spots. These symptoms may be signs of a rare but potentially life-threatening condition called TTP, which has been reported with other medicines in this class.

For more information:
http://www.lilly.com

Editor's Details

Editor
Pharmiweb.com
http://www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 27/08/2010

Advertising